Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Safety, tolerability, and pharmacokinetics of TAS-108 in normal healthy post-menopausal female subjects: a phase I study on single oral dose.

Yamaya H, Yoshida K, Kuritani J, Yonezawa J, Tsuda M, Shindo T, Nagayama S, Buzdar AU.

J Clin Pharm Ther. 2005 Oct;30(5):459-70. Erratum in: J Clin Pharm Ther. 2006 Apr;31(2):204. Yonezawa, JI [corrected to Yonezawa, J].

PMID:
16164493
2.

A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer.

Blakely LJ, Buzdar A, Chang HY, Frye D, Theriault R, Valero V, Rivera E, Booser D, Kuritani J, Tsuda M.

Clin Cancer Res. 2004 Aug 15;10(16):5425-31.

3.

Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer.

Ho DH, Covington W, Brown N, Lin SN, Pazdur R, Huo YY, Creaven PJ, Rustum YM, Meropol NJ, Lassere Y, Kuritani J, Hayakawa T.

Cancer Chemother Pharmacol. 2000;46(5):351-6.

PMID:
11127938
4.
5.

Clinical pharmacology of combined oral uracil and ftorafur.

Ho DH, Covington WP, Pazdur R, Brown NS, Kuritani J, Newman RA, Raber MN, Krakoff IH.

Drug Metab Dispos. 1992 Nov-Dec;20(6):936-40.

PMID:
1362949

Supplemental Content

Loading ...
Support Center